The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity

Journal of Immunology

Volumn 188, Issue 10, 2012, Pages 5012-5019

  Van Der Does, Anne M ^a   Hensbergen, Paul J ^a   Bogaards, Sylvia J ^b   Cansoy, Medine ^a   Deelder, André M ^a   Van Leeuwen, Hans C ^a   Drijfhout, Jan W ^a   Van Dissel, Jaap T ^a   Nibbering, Peter H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBENZOIC ACID DERIVATIVE; ARGININE; CYSTEINE; GLYCYLALANYLALANYLALANYLALANYLSERYLVALYLGLUTAMINYLTRYPTOPHYLCYSTEINYLALANINE; GLYCYLALANYLALANYLARGINYLARGINYLALANYLVALYLGLUTAMINYLTRYPTOPHYLALANYLALANINE; GLYCYLALANYLALANYLARGINYLARGINYLSERYLVALYLGLUTAMINYLTRYPTOPHYLCYSTEINYLALANINE; GLYCYLALANYLARGINYLARGINYLALANYLSERYLVALYLGLUTAMINYLTRYPTOPHYLCYSTEINYLALANINE; GLYCYLARGINYLARGINYLARGINYLARGINYLCYSTEINYLSERYLVALYLGLUTAMINYLTRYPTOPHYLALANINE; GLYCYLARGINYLARGINYLARGINYLARGINYLSERYLVALYLGLUTAMINYLTRYPTOPHYLCYSTEINYLALANINE; GLYCYLLYSYLLYSYLLYSYLLYSYLSERYLVALYLGLUTAMINYLTRYPTOPHYLCYSTEINYLALANINE; LACTOFERRIN; MYELOPEROXIDASE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; COMPUTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MOLECULAR MODEL; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; TARGET CELL;

ANTI-BACTERIAL AGENTS; CELLS, CULTURED; HUMANS; IMMUNOLOGIC FACTORS; LACTOFERRIN; MONOCYTES; PEROXIDASE;

EID: 84861137566     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102777     Document Type: Article

References (39)

1. Valencia, R., L. A. Arroyo, M. Conde, J. M. Aldana, M. J. Torres, F. Fernández- Cuenca, J. Garnacho-Montero, J. M. Cisneros, C. Ortíz, J. Pachón, and J. Aznar. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30: 257-263.
2. Pantosti, A., and M. Venditti. 2009. What is MRSA? Eur. Respir. J. 34: 1190-1196.
3. Migliori, G. B., K. Dheda, R. Centis, P. Mwaba, M. Bates, J. O'Grady, M. Hoelscher, and A. Zumla. 2010. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop. Med. Int. Health. 15: 1052-1066.
4. Hancock, R. E., and R. Lehrer. 1998. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16: 82-88. (Pubitemid 28055477)
5. Hancock, R. E., and H. G. Sahl. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24: 1551-1557. (Pubitemid 44967479)
6. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415: 389-395. (Pubitemid 34100944)
7. Soehnlein, O., A. Zernecke, E. E. Eriksson, A. G. Rothfuchs, C. T. Pham, H. Herwald, K. Bidzhekov, M. E. Rottenberg, C. Weber, and L. Lindbom. 2008. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 112: 1461-1471.
8. Mookherjee, N., D. N. Lippert, P. Hamill, R. Falsafi, A. Nijnik, J. Kindrachuk, J. Pistolic, J. Gardy, P. Miri, M. Naseer, et al. 2009. Intracellular receptor for human host defense peptide LL-37 in monocytes. J. Immunol. 183: 2688-2696.
9. Scott, M. G., E. Dullaghan, N. Mookherjee, N. Glavas, M. Waldbrook, A. Thompson, A. Wang, K. Lee, S. Doria, P. Hamill, et al. 2007. An antiinfective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 25: 465-472. (Pubitemid 46572850)
10. Heilborn, J. D., M. F. Nilsson, G. Kratz, G. Weber, O. Sørensen, N. Borregaard, and M. Sta° hle-Bäckdahl. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120: 379-389. (Pubitemid 36298423)
11. Shaykhiev, R., C. Beisswenger, K. Kändler, J. Senske, A. Püchner, T. Damm, J. Behr, and R. Bals. 2005. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L842-L848. (Pubitemid 41504416)
12. Koczulla, R., G. von Degenfeld, C. Kupatt, F. Krötz, S. Zahler, T. Gloe, K. Issbrücker, P. Unterberger, M. Zaiou, C. Lebherz, et al. 2003. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 111: 1665-1672. (Pubitemid 38057748)
13. van der Does, A. M., S. J. Bogaards, B. Ravensbergen, H. Beekhuizen, J. T. van Dissel, and P. H. Nibbering. 2010. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob. Agents Chemother. 54: 811-816.
14. Davidson, D. J., A. J. Currie, G. S. Reid, D. M. Bowdish, K. L. MacDonald, R. C. Ma, R. E. Hancock, and D. P. Speert. 2004. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172: 1146-1156. (Pubitemid 38113775)
15. Nibbering, P. H., E. Ravensbergen, M. M. Welling, L. A. van Berkel, P. H. van Berkel, E. K. Pauwels, and J. H. Nuijens. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. 69: 1469-1476. (Pubitemid 32187596)
16. Lupetti, A., C. P. Brouwer, S. J. Bogaards, M. M. Welling, E. de Heer, M. Campa, J. T. van Dissel, R. H. Friesen, and P. H. Nibbering. 2007. Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J. Infect. Dis. 196: 1416-1424. (Pubitemid 351412016)
17. Dijkshoorn, L., C. P. Brouwer, S. J. Bogaards, A. Nemec, P. J. van den Broek, and P. H. Nibbering. 2004. The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48: 4919-4921. (Pubitemid 39577708)
18. van der Does, A. M., S. J. Bogaards, L. Jonk, M. Wulferink, M. P. Velders, and P. H. Nibbering. 2010. The human lactoferrin-derived peptide hLF1-11 primes monocytes for an enhanced TLR-mediated immune response. Biometals 23: 493-505.
19. Nell, M. J., G. S. Tjabringa, A. R. Wafelman, R. Verrijk, P. S. Hiemstra, J. W. Drijfhout, and J. J. Grote. 2006. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 27: 649-660.
20. Kettle, A. J., C. A. Gedye, and C. C. Winterbourn. 1997. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem. J. 321: 503-508. (Pubitemid 27056501)
21. Carpena, X., P. Vidossich, K. Schroettner, B. M. Calisto, S. Banerjee, J. Stampler, M. Soudi, P. G. Furtmüller, C. Rovira, I. Fita, and C. Obinger. 2009. Essential role of proximal histidine-asparagine interaction in mammalian peroxidases. J. Biol. Chem. 284: 25929-25937.
22. Hunter, H. N., A. R. Demcoe, H. Jenssen, T. J. Gutteberg, and H. J. Vogel. 2005. Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother. 49: 3387-3395. (Pubitemid 41060587)
23. Comeau, S. R., D. Kozakov, R. Brenke, Y. Shen, D. Beglov, and S. Vajda. 2007. ClusPro: performance in CAPRI rounds 6-11 and the new server. Proteins 69: 781-785. (Pubitemid 350210138)
24. Zeng, J., and R. E. Fenna. 1992. X-ray crystal structure of canine myeloperoxidase at 3 A resolution. J. Mol. Biol. 226: 185-207.
25. Winterbourn, C. C. 1985. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim. Biophys. Acta 840: 204-210. (Pubitemid 15049536)
26. Futaki, S., I. Nakase, A. Tadokoro, T. Takeuchi, and A. T. Jones. 2007. Argininerich peptides and their internalization mechanisms. Biochem. Soc. Trans. 35: 784-787. (Pubitemid 47310368)
27. Herce, H. D., and A. E. Garcia. 2007. Cell penetrating peptides: how do they do it? J. Biol. Phys. 33: 345-356.
28. Haegens, A., P. Heeringa, R. J. van Suylen, C. Steele, Y. Aratani, R. J. O'Donoghue, S. E. Mutsaers, B. T. Mossman, E. F. Wouters, and J. H. Vernooy. 2009. Myeloperoxidase deficiency attenuates lipopolysaccharideinduced acute lung inflammation and subsequent cytokine and chemokine production. J. Immunol. 182: 7990-7996.
29. Midwinter, R. G., M. C. Vissers, and C. C. Winterbourn. 2001. Hypochlorous acid stimulation of the mitogen-activated protein kinase pathway enhances cell survival. Arch. Biochem. Biophys. 394: 13-20. (Pubitemid 32948279)
30. Lau, D., H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber, U. M. Gehling, J. Brümmer, V. Rudolph, T. Münzel, T. Heitzer, et al. 2005. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. USA 102: 431-436. (Pubitemid 40116784)
31. Hsieh, S. C., H. S. Yu, S. H. Cheng, K. J. Li, M. C. Lu, C. H. Wu, C. Y. Tsai, and C. L. Yu. 2007. Anti-myeloperoxidase antibodies enhance phagocytosis, IL-8 production, and glucose uptake of polymorphonuclear neutrophils rather than anti-proteinase 3 antibodies leading to activation-induced cell death of the neutrophils. Clin. Rheumatol. 26: 216-224. (Pubitemid 46020248)
32. Zhang, R., M. L. Brennan, X. Fu, R. J. Aviles, G. L. Pearce, M. S. Penn, E. J. Topol, D. L. Sprecher, and S. L. Hazen. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286: 2136-2142. (Pubitemid 34041599)
33. Green, P. S., A. J. Mendez, J. S. Jacob, J. R. Crowley, W. Growdon, B. T. Hyman, and J. W. Heinecke. 2004. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 90: 724-733. (Pubitemid 38989404)
34. Malle, E., T. Buch, and H. J. Grone. 2003. Myeloperoxidase in kidney disease. Kidney Int. 64: 1956-1967. (Pubitemid 37449530)
35. Malle, E., P. G. Furtmüller, W. Sattler, and C. Obinger. 2007. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol. 152: 838-854. (Pubitemid 350100486)
36. Liu, H. R., L. Tao, E. Gao, Y. Qu, W. B. Lau, B. L. Lopez, T. A. Christopher, W. Koch, T. L. Yue, and X. L. Ma. 2009. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation-a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc. Res. 81: 344-352.
37. Kutter, D., P. Devaquet, G. Vanderstocken, J. M. Paulus, V. Marchal, and A. Gothot. 2000. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104: 10-15.
38. Askari, A. T., M. L. Brennan, X. Zhou, J. Drinko, A. Morehead, J. D. Thomas, E. J. Topol, S. L. Hazen, and M. S. Penn. 2003. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med. 197: 615-624. (Pubitemid 36314656)
39. Velden, W. J., T. M. van Iersel, N. M. Blijlevens, and J. P. Donnelly. 2009. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med. 7: 44.